Sarepta Therapeutics price to sales ratio SRPT

Market value divided by revenue over the last twelve months, since 2018.

Today, Oct 23, 2026: 0.9×
9-year median: 11.1×
Against its 9-year history: 12th; percentile: 0 is its lowest day, 100 its highest
9-year range: 0.5× to 45.3×
Peer median: 1.8×

Sarepta Therapeutics' price to sales ratio is 0.9× as of Oct 23, 2026.

That is below its 9-year median of 11.1×, lower than on 88% of days in the last 9 years.

Over that time it ranged from 0.5× in Jul 2025 to 45.3× in Jun 2018.

The median for 10 large drugmakers of a similar size is 1.8×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	0.9×	0.7×	1.2×
2025	1.0×	0.5×	7.4×
2024	7.1×	6.1×	11.6×
2023	8.2×	6.6×	14.7×
2022	13.0×	7.5×	13.0×
2021	12.1×	9.3×	15.7×
2020	27.2×	17.8×	32.3×
2019	26.5×	16.2×	35.8×
2018	26.3×	24.0×	45.3×

Against its peers

Companies in Drug Manufacturers - General nearest Sarepta Therapeutics' size, closest first, today.

Company	Price to sales ratio
SRPTSarepta Therapeutics	0.9×
ANIPANI Pharmaceuticals	1.7×
HRMYHarmony Biosciences	2.2×
PAHCPhibro Animal Health	1.0×
PBHPrestige Consumer Healthcare	2.0×
ANABAnaptysbio	n/m
PCRXPacira BioSciences	1.9×
NRIXNurix Therapeutics	3.9×
OMEROmeros	n/m
AMPHAmphastar Pharmaceuticals	1.5×
OGNOrganon	0.6×
Peer median	1.8×

Where Sarepta Therapeutics ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Sarepta Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.